And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

The singer and alligator tour guide tied the knot in Louisiana on Sept. 26, 2024 Lana Del Rey/Instagram Lana Del Rey is giving her fans a glimpse into married life. While promoting her upcoming ...

and inactivated trivalent influenza vaccine (TIV; Fluarix™, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to ...

GlaxoSmithKline Pharmaceuticals Limited is ... In September 2020, the Company launched tetravalent influenza flu vaccine, Fluarix Tetra to help combat influenza.In June, 2021 Company launched ...

Portfolio manager Dan LeVan heads Trivalent, a Boston-based international equity boutique that specializes in non-US developed- and emerging-markets strategies under Victory Capital's umbrella.

Engerix-B (GlaxoSmithKline) 72 hr Manufacturer Immune globulin (human) Gamastan S/D (Bayer) Cumulative exposure for 7 days Manufacturer Influenza virus vaccine Fluarix (GlaxoSmithKline ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.